Vizimpro (Dacomitinib)

Save up to 88% buying Vizimpro (also called Dacoplice).  Product is manufactured in Europe.  Same Pfizer medicine at huge discount!

Manufacturing site for Dacoplice is exactly the same as Vizimpro for Europe: M/s. Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg Mooswaldallee 1 Freiburg - 79090 (Germany)

Dacoplice information from Pfizer

Vizimpro   European product information showing same manufacturing site as Dacoplice
 

Information about Vizimpro(Dacomitinib)
 

Vizimpro (Dacomitinib) is an oral medication used in the treatment of non-small cell lung cancer (NSCLC). It is a tyrosine kinase inhibitor (TKI) that works by blocking specific proteins involved in the growth and spread of cancer cells. Dacomitinib targets the epidermal growth factor receptor (EGFR) pathway, which is often dysregulated in certain cancers, including NSCLC. It is particularly used for patients with advanced NSCLC who have a specific genetic mutation in the EGFR gene.

Product Highlights

• Vizimpro is primarily indicated for the first-line treatment of metastatic non-small cell lung cancer in patients who test positive for EGFR mutations (specifically exon 19 deletions or exon 21 L858R substitution). It is typically used when traditional chemotherapy options are not ideal or have been unsuccessful.
• The drug is used specifically for patients whose lung cancer is driven by a mutation in the EGFR gene, which is involved in the growth of cancer cells.

Key Ingredient

• Dacomitinib

Key Benefits

• Vizimpro is a targeted treatment that focuses specifically on cancer cells with EGFR mutations, potentially offering a more effective treatment with fewer side effects compared to traditional chemotherapy.
• Clinical trials have shown that dacomitinib can significantly improve progression-free survival (PFS) in patients with advanced NSCLC who have EGFR mutations compared to other treatments.
• Vizimpro is taken as a once-daily oral tablet, offering convenience over intravenous chemotherapy or more complex treatment regimens.
• It targets the EGFR mutations directly, providing a specialized treatment option for patients with these specific genetic alterations in their cancer.

Direction of Use

• The recommended dose for Vizimpro is typically 45 mg once daily. The dose should be taken at the same time each day, with or without food.
• Vizimpro tablets should be swallowed whole with a glass of water. Do not break, crush, or chew the tablets. 
• To maintain the effectiveness of the treatment, take Vizimpro consistently at the prescribed dose and schedule. If a dose is missed, take it as soon as possible, but skip the missed dose if it's almost time for the next one. Do not take more than the prescribed dose to compensate for a missed dose. 

Safety Concerns

• Diarrhea is a common side effect of Vizimpro, which can sometimes be severe. Patients should be monitored and treated for diarrhea, as dehydration can result from prolonged diarrhea.
• Rash, acne, and other skin reactions are common, and severe rashes may require dose modifications or discontinuation of therapy.
• Severe or life-threatening lung problems (interstitial lung disease or pneumonitis) can occur and require immediate medical attention. Symptoms may include shortness of breath, cough, and fever.
• In addition to diarrhea, nausea and vomiting may occur in some patients.
• Elevated liver enzymes and liver dysfunction can occur. Regular monitoring of liver function is advised.
• Vizimpro may cause a prolonged QT interval (a measure of heart rhythm), increasing the risk of serious arrhythmias. ECG monitoring may be required for patients with pre-existing heart conditions.

Avoid Vizimpro (Dacomitinib) If

• Do not use Vizimpro if you have a known allergy to dacomitinib or any of its components.
• Vizimpro can harm an unborn baby. It is classified as a pregnancy category D drug (positive evidence of risk). Women should avoid becoming pregnant while taking Vizimpro, and pregnancy testing should be done before starting treatment.
• It is not known whether dacomitinib passes into breast milk, so breastfeeding should be avoided during treatment.
• Patients with moderate to severe liver dysfunction should avoid using Vizimpro, as liver toxicity may be exacerbated.
• Patients with a history of lung disease, particularly interstitial lung disease or pneumonitis, should avoid Vizimpro due to the increased risk of serious lung complications.
• Patients with a history of QT prolongation or other heart conditions should not take Vizimpro unless closely monitored, as it can further prolong the QT interval.